United States: FDA Issues Revised Draft Guidance On Disclosures Of Risk Information In Consumer-Friendly Print Advertisements And Promotional Labeling

The U.S. Food and Drug Administration (FDA) recently released its Revised Draft Guidance entitled "Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs" (Draft Guidance).  The Draft Guidance significantly revises the FDA's January 2004 draft guidance on the brief summary requirement for disclosures in consumer-directed print advertisements and also covers promotional labeling.  In the revised Draft Guidance, the agency strongly recommends the use of either a Drug Facts Box or a series of questions and answers for displaying risk information in consumer-directed print advertisements and promotional labeling in order to improve patient comprehension of important product-related information.  According to the FDA, these "research-tested" formats are designed to be an alternative to the use of lengthy and technical risk information that currently appears in traditional print advertisements and promotional labeling.

Scope of the Draft Guidance

The Draft Guidance applies to prescription drug and biological product print advertisements and promotional labeling, if such materials are directed to consumers.  The Draft Guidance does not apply to promotional materials directed at health care professionals, or to radio, television or broadcast advertisements.  Additionally, the Draft Guidance does not address risk information included in the main portion of the advertisement or promotional labeling.  Rather, the Draft Guidance focuses on a new "consumer brief summary."

A New Approach to the Content and Format of Brief Summary and Adequate Directions for Use Requirements: The Consumer Brief Summary

The Draft Guidance discusses how manufacturers, packers, distributors and those working on their behalf (firms) traditionally approach the "brief summary" and "adequate directions for use" requirements contained in the Federal Food, Drug, and Cosmetic Act in the context of consumer-directed prescription advertisements and promotional labeling pieces.  The brief summary requirement mandates the disclosure of each side effect, warning, precaution and contraindication from the prescription drug's labeling in drug advertisements.  Currently, firms typically meet the brief summary requirement by providing the entire risk-related portion of the FDA-approved package insert.

The adequate directions for use requirement provides that prescription drug promotional labeling materials distributed by or on behalf of a firm must contain adequate information for use and additional labeling information as set forth in 21 C.F.R. § 201.100(d).  Firms generally fulfill the adequate directions for use requirement by including the full package insert.

In the Draft Guidance, the FDA sets forth its strongly preferred streamlined approach for fulfilling the brief summary and adequate directions for use requirements.  The FDA refers to its recommended approach of combining the information in the brief summary and adequate directions for use requirements as the "consumer brief summary."  The FDA's suggested approach allows firms to provide consumers with the same content in print advertisements and promotional labeling pieces.

The FDA states that it "does not intend to object if a firm does not include 'each specific side effect and contraindication'" from the package insert in the brief summary.  Similarly, if firms follow the Draft Guidance, the FDA states that it "does not intend to object for failure to include the entire [package insert] to fulfill the requirements of [21 C.F.R. §] 201.100(d) for consumer-directed promotional labeling pieces."  

The Draft Guidance discusses three key aspects of the consumer brief summary: 

  • Language and readability
  • Content
  • Format

Language and Readability Recommendations

The Draft Guidance was informed by studies of how well consumers absorbed the detailed information contained in the package insert, which was the means of conveying the required information in the traditional approach.  The studies found that this lengthy technical information was difficult for consumers to understand.  In order to create advertisements and promotional labeling pieces that are more consumer friendly, the FDA recommends that firms take the following steps:

  • Write for varying levels of literacy skills
  • Avoid technical, scientific and medical jargon
  • Use a conversational tone
  • Use signals, such as headlines and subheadings
  • Repeat the use of logos and branded colors from the main body of the advertisement in the consumer brief summary
  • Maximize background or white space to improve readability
  • Select font sizes and styles based on readability
  • Use text boxes with headings, bullets and other attention-drawing mechanisms

Content Recommendations

The consumer brief summary should focus on the most significant clinical information and the most serious and common risks.  To determine which serious and common risks to include in the consumer brief summary and which to omit, the Draft Guidance recommends that firms take the following steps:

  • Review risk information in FDA-approved patient labeling and Medication Guides
  • Include information about relevant drug risks that does not appear in the patient labeling
  • Examine the criteria for selecting risk information for the Highlights of Prescribing Information for risk topics to add to the consumer brief summary, but provide more detailed and material information than the information that appears in the Highlights
  • Display information in the consumer brief summary in an order substantially similar to the Highlights of Prescribing Information

According to the Draft Guidance, the following information should be included in the consumer brief summary:

  • Boxed Warning (if applicable to the particular drug or biologic)
  • All contraindications
  • From the Warnings and Precautions sections of the package insert, the most clinically significant information, including 
    o Information that would affect a decision to prescribe or take a drug
    o Whether monitoring or laboratory tests are needed during treatment
    o Special precautions not included in other parts of the package insert
    o Measures that patients should take to prevent or mitigate harm

The FDA also recommends that the consumer brief summary include the following:

  • The most frequently occurring adverse reactions for each indication for which the product is being promoted, listed in the same order as in the package insert
  • Serious adverse reactions and other important adverse reactions, unless mentioned elsewhere
  • Material information regarding risks, including severity or early warning signs of risks
  • The indication for the use being promoted and information relevant to each indication being promoted
  • Clinically significant drug interactions
  • Topics consumers should discuss with their health care providers
  • Information relating to special populations of concern based on the drug's safety profile
  • A reminder that the information in the summary is not comprehensive
  • A suggestion that consumers speak to their health care provider or pharmacist
  • A toll-free number or website where consumers can find the FDA-approved labeling

The Draft Guidance also outlines topics that can be excluded from the consumer brief summary:

  • Information that appears in the Directions for Use section
  • Dosage, administration and clinical pharmacology information
  • How the drug is supplied
  • How long the drug takes to work

Format Recommendations

The FDA's recommended formats for presenting risk information to consumers in the consumer brief summary are as follows:

  • A Prescription Drug Facts Box similar to the Over-the-Counter Drug Facts Box
  • A Question and Answer format

Comparison of the 2004 Draft Guidance and the 2015 Revised Draft Guidance

In the revised Draft Guidance, the FDA expanded the application of the 2004 draft guidance to biologics and consumer-directed promotional labeling, and changed its position regarding how firms should present risk information.  In the 2004 version, the FDA offered firms three options for presenting risk information in consumer-directed print advertisements:

  • Present all risk information from the FDA-approved professional labeling
  • Reproduce FDA-approved patient labeling, in its entirety or without less important risk information
  • Provide risk information that would be appropriate for the FDA-approved Highlights of Prescribing Information

Although the FDA emphasized that it would not object to advertisements that omitted less important risk information in 2004, the agency still endorsed the presentation or reproduction of all risk information in consumer-directed advertisements.

In contrast, the 2015 Draft Guidance strongly recommends against the inclusion of all risk information and verbatim reproductions of risk information.  Both versions of the Draft Guidance similarly discourage firms from using small type and scientific, technical and medical terms that are less likely to be understood by consumers.

Although the 2004 draft guidance did not provide specific "research-tested" formats for presenting risk information, it contained similar recommendations to the 2015 Draft Guidance regarding content.  For example, the 2004 draft guidance recommended that firms include a reminder that the information presented is not comprehensive and a toll-free number or website where consumers could find additional information.  The 2015 Draft Guidance additionally recommends that each advertisement suggest that the consumer speak with his or her health care provider or pharmacist.

Implications for Regulated Manufacturers, Packers and Distributors

The agency's approach is a constructive effort to optimize readability and consumer comprehension of important risk information presented in prescription drug materials.  By offering an alternative to the inclusion of the entire risk-related section of the FDA-approved package insert in print advertisements or the full package insert in promotional labeling pieces, the revised Draft Guidance offers a new regulatory approach to communicating with consumers in advertising and promotional materials.  However, the revised draft guidance will likely impose new challenges for firms seeking to adapt their overall advertising and promotion program to these changing regulatory enforcement policies, while also mitigating risk with regard to product liability and consumer protection laws.

Comment Deadline

Firms should consider submitting comments regarding the Draft Guidance to the FDA.  Any comments must be submitted by May 11, 2015, in order to be considered by the agency before it begins work on the final guidance document.

FDA Issues Revised Draft Guidance On Disclosures Of Risk Information In Consumer-Friendly Print Advertisements And Promotional Labeling

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.